Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with short-course chemoradiotherapy and stereotactic radiotherapy for metastatic or unresectable oesophageal cancer
ACTRN12619001371189Phase 2Recruiting
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Nov 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, carboplatin and paclitaxel in esophageal cancer and esophagogastric junction cancer, sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoint: Progression-free survival rate at 6 months. Started Nov 2019; status: recruiting.
02
Drugs
durvalumabcarboplatinpaclitaxel
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on ACTRN12619001371189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001371189.